Slide 1: Leading the NeXT Generation of Cancer Testing
Leading the NeXT Generation of Cancer Testing Investor Presentation May 2025 © 2025 Personalis, Inc. All rights reserved. All trademarks are the property of Personalis, Inc. or their respective owners. All products described here are for Research Use Only and not for use in diagnostic procedures (ex
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and the accompanying oral presentation contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained in this presen
Slide 3: Who we are: Leaders in early recurrence detection for cancer survivors
Who we are: Leaders in early recurrence detection for cancer survivors PERSONALIS FAST FACTS 2011 45+ ~500K 100K 100+ YEAR FOUNDED ISSUED PATENTS HUMAN SAMPLES SEQUENCED SQ FT OF LAB & OFFICE FACILITIES PUBLICATIONS & POSTERS 50+ CLIA / CAP / NYSDOH / ISO 13485 BIOPHARMA PARTNERS QMS & REGULATORY CR
Slide 4: Strong Execution in Q1-2025 and Achievement of Milestones
Strong Execution in Q1-2025 and Achievement of Milestones First Quarter of 2025 Key Financial Updates 2024-25 Key Business Accomplishments • Total revenue of $20.6M (+6% YoY) ✓ Delivered 2,184 molecular tests in Q1-2025, up 52% Q/Q; more than 5,400 cumulative commercial tests to — Biopharma Y/Y grow
Slide 5: Driving Capital-Efficient Oncology Growth
Driving Capital-Efficient Oncology Growth Excludes revenue from the VA MVP Capital-Efficient Model with a Low-Cost Foundation $ in Millions 2020 2021 2022 2023 2024 Reduced 2024 cash usage to lower levels of ~$47M by increasing ~$47M revenue & gross profit dollars and reducing expenses $77 Raised ~$
Slide 6: 2025 - We Expect to Realize High Strategic Value
2025 - We Expect to Realize High Strategic Value Key Milestones ✓ Generate additional clinical evidence for MRD with NeXT Personal in three key indications (lung, breast, and immunotherapy (IO) monitoring) through KOL collaborations • Submit for Medicare reimbursement once manuscripts are accepted f
Slide 7: Next Generation Ultra-Sensitive MRD Testing
Next Generation Ultra-Sensitive MRD Testing
Slide 8: A cancer patient's journey is filled with uncertainty…
A cancer patient’s journey is filled with uncertainty… How serious is my cancer? Is my cancer treatment working? Is my cancer gone? If my cancer comes back, will I catch it in time? 8
Slide 9: … and existing options don't provide confidence
… and existing options don’t provide confidence Tumors aren’t always detectable by imaging Imaging can be non-specific Time, cost and radiation can limit frequent use Blood tests alone may have limited sensitivity The ultra-sensitivity of NeXT Personal Dx is expected to provide a solution for these
Slide 10: Entering the Next Generation of Ultra-Sensitive MRD Testing
Entering the Next Generation of Ultra-Sensitive MRD Testing Unique Features of NeXT Personal NeXT Personal® Dx Creating A Better Management Paradigm For Whole Genome Sequencing Cancer Patients • NeXT Personal Dx LDT for MRD launched October 2023 Large Personalized Panel (Up to ~1,800 Variants) • Hig
Slide 11: Demonstrating Landmark Performance with TRACERx Data
Demonstrating Landmark Performance with TRACERx Data Preliminary Data Highlights Promise of Ultra-Sensitive Approach for Post-Operative Disease Stratification Surgery +/- Adjuvant Recurrence on Imaging ✓ Best overall landmark performance to date in TRACERx early-stage lung (NeXT 331 days median lead
Slide 12: Capital-Efficient Strategy to Commercialize NeXT Personal Dx
Capital-Efficient Strategy to Commercialize NeXT Personal Dx 1st-in-class, ultra-sensitive First-in-class, MRD ultra-sensitive test MRD testpoised poised toto capture capture shareshare in (1) in a $20B+ a market $30B+ market Partner with Top KOLs to Commercialize Develop Clinical Evidence with Part
Slide 13: Strategic Indication Selection Focused on Cancers Where Ultra-Sensitivity Brings the Most Value
Strategic Indication Selection Focused on Cancers Where Ultra-Sensitivity Brings the Most Value NeXT Personal® Dx’s sensitivity (up to 10x-100x greater analytical sensitivity - ~1 part per million) unlocks opportunity to address recurrence earlier and to guide treatment decisions better than current
Slide 14: 2024-25 are Key Years for Clinical Evidence Generation
2024-25 are Key Years for Clinical Evidence Generation Early 2024 Mid 2024 Late 2024 2025E UKE – Melanoma Royal Marsden – Breast Multiple Subtypes Dana Farber – Breast HER2+ TRACERx – NSCLC Ph. 2 (Ph.1 in 2023 at ESMO) VHIO – Pan-cancer Duke – Gastric Curie Institute – TNBC B-Stronger – TNBC - Utili
Slide 15: Deep Experience in Biopharma Accelerates NeXT Personal Adoption By Establishing Clinical Utility
Deep Experience in Biopharma Accelerates NeXT Personal Adoption By Establishing Clinical Utility Key Biopharma Players Leverage Our Core Platform Today 16 15 14 17 18 of Top 20 Immuno- Targeted Cell Personalized Pharma Oncology Therapy Therapy Cancer Vaccine Trial Enrollment & Companion NeXT Persona
Slide 16: Personalizing Cancer Vaccines Provides Tremendous Upside
Personalizing Cancer Vaccines Provides Tremendous Upside Building Personalized Powers personalized Monitoring Therapy Enables patient- Therapies vaccine design Response specific monitoring Enabled by Personalis Enabled by Personalis Tumor FFPE and Exome & Computational Neoantigen mRNA Personalized R
Slide 17: Tempus Partnership: Capital-Efficient Way to Drive Accelerated Growth and Adoption of NeXT Personal for MRD
Tempus Partnership: Capital-Efficient Way to Drive Accelerated Growth and Adoption of NeXT Personal for MRD NeXT Personal® Dx • Tempus, a leader in artificial intelligence and precision medicine, has selected NeXT Personal Dx as its MRD test of choice + • Leverage Tempus’ leading sales channel to co
Slide 18: Leveraging Core IP and Proven Executional Strengths to Drive Continued Oncology Platform Growth
Leveraging Core IP and Proven Executional Strengths to Drive Continued Oncology Platform Growth ~500,000 human Scaling operations Differentiated Intellectual samples & for clinical testing QMS and property ~200,000 human and biopharma regulatory protection genomes including with credentials includin
Slide 19: 2025 is Expected to be a Key Value Inflection Point for Personalis
2025 is Expected to be a Key Value Inflection Point for Personalis Core business poised to First-in-class ultra-sensitive deliver strong growth MRD test offers unique across MRD and opportunity to capture biopharma share in a $20B+(1) market Significant growth Capital-efficient opportunity and early
Slide 20: Thank You!
Thank You! © 2025 Personalis, Inc. All rights reserved. All trademarks are the property of Personalis, Inc. or their respective owners. All products described here are for Research Use Only and not for use in diagnostic procedures (except as specifically noted).